Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
Open Access
- 8 June 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 43 (7), 615-617
- https://doi.org/10.1007/s40264-020-00954-z
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Liver injury during highly pathogenic human coronavirus infectionsLiver International, 2020
- Liver injury in COVID-19: management and challengesThe Lancet Gastroenterology & Hepatology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV CohortAmerican Journal of Clinical Dermatology, 2012
- Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patientIndian Journal of Pharmacology, 2012
- Severe Cutaneous Reactions Associated with the Use of Human Immunodeficiency Virus MedicationsActa Dermato-Venereologica, 2003
- Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registryJournal of Clinical Epidemiology, 1996
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisThe New England Journal of Medicine, 1995